A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin
LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.